NZ510167A - Alginate capsules for use in the treatment of brain tumour - Google Patents

Alginate capsules for use in the treatment of brain tumour

Info

Publication number
NZ510167A
NZ510167A NZ510167A NZ51016799A NZ510167A NZ 510167 A NZ510167 A NZ 510167A NZ 510167 A NZ510167 A NZ 510167A NZ 51016799 A NZ51016799 A NZ 51016799A NZ 510167 A NZ510167 A NZ 510167A
Authority
NZ
New Zealand
Prior art keywords
cells
alginate
tumour
encapsulated
producer cell
Prior art date
Application number
NZ510167A
Other languages
English (en)
Inventor
Rolf Bjerkvig
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Publication of NZ510167A publication Critical patent/NZ510167A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
NZ510167A 1998-08-26 1999-08-25 Alginate capsules for use in the treatment of brain tumour NZ510167A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO983911A NO983911D0 (no) 1998-08-26 1998-08-26 Alginatkapsler til bruk ved behandling av hjernesvulst
PCT/NO1999/000266 WO2000012066A1 (en) 1998-08-26 1999-08-25 Alginate capsules for use in the treatment of brain tumour

Publications (1)

Publication Number Publication Date
NZ510167A true NZ510167A (en) 2003-09-26

Family

ID=19902361

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ510167A NZ510167A (en) 1998-08-26 1999-08-25 Alginate capsules for use in the treatment of brain tumour

Country Status (16)

Country Link
US (2) US6926888B1 (tr)
EP (1) EP1105100A1 (tr)
JP (1) JP2002523445A (tr)
KR (1) KR100699286B1 (tr)
CN (1) CN1191823C (tr)
AU (1) AU760433B2 (tr)
BR (1) BR9913326A (tr)
CA (1) CA2340325A1 (tr)
IL (2) IL141501A0 (tr)
IS (1) IS5855A (tr)
NO (2) NO983911D0 (tr)
NZ (1) NZ510167A (tr)
RU (1) RU2229287C2 (tr)
TR (1) TR200100583T2 (tr)
WO (1) WO2000012066A1 (tr)
ZA (1) ZA200101464B (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941505D1 (de) * 1998-02-03 2009-11-19 Ct Disease Contr & Prevention Verfahren zur herstellung rekombinanter, lipid-modifizierter psaa proteine und deren verwendung
SE530184C2 (sv) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
KR100969516B1 (ko) * 2007-08-16 2010-07-09 경북대학교 산학협력단 세포 생존력 및 기능을 향상시키는 도우넛형 세포 캡슐의제조 방법 및 세포 치료적용
US9555007B2 (en) 2013-03-14 2017-01-31 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5073491A (en) * 1988-12-23 1991-12-17 Hoffman-La Roche Inc. Immobilization of cells in alginate beads containing cavities for growth of cells in airlift bioreactors
US5459054A (en) * 1989-12-05 1995-10-17 Neocrin Company Cells encapsulated in alginate containing a high content of a- l- guluronic acid
US5166137A (en) 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
ATE156344T1 (de) 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
ES2125630T3 (es) 1994-07-08 1999-03-01 Baxter Int Dispositivo implantable que contiene celulas tumorales, para el tratamiento del cancer.
US6126936A (en) * 1995-03-10 2000-10-03 Biohybrid Technologies Llc Microcapsules and composite microreactors for immunoisolation of cells
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
CN1296477C (zh) 1996-04-03 2007-01-24 罗格森研究所 含有抑制癌细胞增殖的因子的条件培养基及其制备方法
AU2674097A (en) * 1996-04-17 1997-11-07 Cytotherapeutics, Inc. Method and device for delivery of apoptosis-inducing molecules
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
DE19638745C2 (de) * 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US6368612B1 (en) * 1997-12-12 2002-04-09 Biohybrid Technologies Llc Devices for cloaking transplanted cells

Also Published As

Publication number Publication date
ZA200101464B (en) 2002-05-21
BR9913326A (pt) 2001-05-15
AU5538999A (en) 2000-03-21
CA2340325A1 (en) 2000-03-09
JP2002523445A (ja) 2002-07-30
CN1320032A (zh) 2001-10-31
KR100699286B1 (ko) 2007-03-26
EP1105100A1 (en) 2001-06-13
NO20010960D0 (no) 2001-02-26
RU2229287C2 (ru) 2004-05-27
CN1191823C (zh) 2005-03-09
NO983911D0 (no) 1998-08-26
IS5855A (is) 2001-02-22
IL141501A0 (en) 2002-03-10
WO2000012066A1 (en) 2000-03-09
IL141501A (en) 2006-10-31
NO20010960L (no) 2001-04-25
TR200100583T2 (tr) 2001-06-21
US6926888B1 (en) 2005-08-09
AU760433B2 (en) 2003-05-15
US20050180960A1 (en) 2005-08-18
KR20010074851A (ko) 2001-08-09

Similar Documents

Publication Publication Date Title
US11576862B2 (en) Methods and compositions for preparing a silk microsphere
ES2406716T3 (es) Dispositivo micronizado para el suministro de moléculas activas biológicamente y método de uso del mismo
JP6850734B2 (ja) 眼の障害の処置のためのカプセル化細胞療法の使用
EP3424498B1 (en) Tumour therapeutic monoclonal antibody nano-capsule and preparation method and use thereof
Chen et al. Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy
JP2001519692A (ja) 非ステロイド性抗炎症剤による、移植装置に対する線維形成応答の阻害
CN104066425A (zh) 特异性靶向癌细胞的输送系统及其使用方法
US20050180960A1 (en) Alginate capsules for use in the treatment of brain tumour
Zhu et al. Novel biomimetic mesoporous silica nanoparticle system possessing targetability and immune synergy facilitates effective solid tumor immuno-chemotherapy
US20230250183A1 (en) Polypeptide that specifically binding to cd123 protein, polypeptide complexe, co-delivery system and preparation method and use thereof
Ljubimov et al. Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic
CZ392497A3 (cs) Buněčná linie produkující sloučeniny s analgetickým účinkem pro léčení bolesti
US20130202625A1 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
US11369572B2 (en) Fas (Apo-1,CD95) targeted platforms for intracellular drug delivery
MXPA01001987A (en) Alginate capsules for use in the treatment of brain tumour
CN110404077A (zh) 肿瘤ecm降解和/或抑制剂及其成套药盒和应用
Ma et al. Enhanced EPR effects by tumour stromal cell mimicking nanoplatform on invasive pituitary adenoma
AU777526B2 (en) Pharmaceutical compositions comprising immortalised endothelial cells
Zhang et al. Novel biomimetic mesoporous silica nanoparticles system possessed targetability and immune synergy to promote solid tumor immuno-chemotherapy efficacy
JP2002069005A (ja) 固形癌治療用製剤
Li et al. A novel follicular dendritic cell molecule, 8D6 collaborates with CD44 in
Chen Direct intracerebral drug delivery for the treatment of malignant glioma

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)